Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
Completed
- Conditions
- Hepatitis C
- Interventions
- Biological: Blood Sampling
- Registration Number
- NCT05449847
- Lead Sponsor
- Benha University
- Brief Summary
100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Complicated hepatitis C by HCC
- Complicated hepatitis C by liver cirrhosis
- Complicated hepatitis C by steatohepatitis
- uncomplicated hepatitis C
Exclusion Criteria
- pre-portal fibrosis secondary to previous bilharzial disease
- pre-portal fibrosis secondary to alcoholic fatty liver
- The presence of hepatic malignancy other than HCC
- decompensated cirrhosis
- hepatorenal failure
- hepatic manifestations of congestive heart failure.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Complicated HCV Blood Sampling - Non Complicated HCV Blood Sampling -
- Primary Outcome Measures
Name Time Method Relation between MicroRNA and HCV 12 months The ability of estimation of plasma microRNA 21 and 126 to differentiate between uncomplicated and complicated HCV patients
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Benha university
🇪🇬Banhā, El- Qalyobia, Egypt